论文部分内容阅读
目的观察胸腺肽α1联合促肝细胞生长素治疗中晚期肝硬化腹水的临床疗效。方法 42例中晚期肝硬化腹水患者随机分为治疗组21例和对照组21例。对照组予以综合保肝、降酶、利尿治疗,治疗组在对照组治疗基础上加用胸腺肽α1联合促肝细胞生长素治疗,治疗16周后观察2组肝功能、凝血酶原时间(PT)和腹水吸收等情况。结果 2组治疗后肝功能明显好转,ALB高于治疗前,差异均有统计学意义(P<0.01);治疗组腹水吸收总有效率为75.0%高于对照组的57.1%,差异有统计学意义(P<0.01)。结论胸腺肽α1联合促肝细胞生长素治疗中晚期肝硬化腹水疗效显著,有助于肝功能恢复及腹水减少。
Objective To observe the clinical efficacy of thymosin α1 in combination with hepatocyte growth-regulating hormone in the treatment of advanced ascites due to cirrhosis. Methods 42 patients with advanced cirrhosis and ascites were randomly divided into treatment group (n = 21) and control group (n = 21). The control group was given comprehensive protection of the liver, reducing enzyme and diuresis. The treatment group was treated with thymosin α1 plus hepatocyte growth-promoting factor on the basis of the control group. After 16 weeks of treatment, the liver function, prothrombin time (PT) And ascites absorption and so on. Results The liver function of the two groups improved obviously, ALB was higher than that before treatment (P <0.01). The total effective rate of ascites absorption in the treatment group was 75.0%, which was higher than that in the control group (57.1%), the difference was statistically significant Significance (P <0.01). Conclusions The combination of thymosin α1 and hepatocyte growth-promoting factor in the treatment of ascites caused by advanced cirrhosis is significant, which is helpful for the recovery of liver function and the reduction of ascites.